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This phase I study investigated the maximum tolerated dose and pharmacokinetics of a 3-weekly administration of BMS-188797, a
paclitaxel derivate, at three dose levels (DLs) (80, 110 and 150mgm
 2 DL), combined with cisplatin (standard dose 75mgm
 2). In
16 patients with advanced malignancies treated, one patient experienced dose-limiting febrile neutropenia, sepsis and severe colitis at
the 150mgm
 2 DL; at the 110mgm
 2 DL one episode of dose-limiting grade 3 diarrhoea/nausea occurred. Grade 3/4
haematological toxicities were leucopenia/neutropenia; grade 3 nonhaematological toxicities were neuropathy, nausea, diarrhoea and
stomatits. Objective response was seen in four patients, with three complete remissions in ovarian and cervical cancer patients.
Pharmacokinetics of BMS-188797 appeared linear through the 110mgm
 2, but not through the 150mgm
 2 DL. The mean7SD
values for clearance, distribution volume at steady state and terminal half-life during cycle 1 were 317760mlmin
 1m
 2,
258796lm
 2 and 30.877.7h, respectively. The maximum tolerated and recommended phase II dose for BMS-188797 was
110mgm
 2 (1-h infusion, every 3 weeks) combined with cisplatin 75mgm
 2.
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Paclitaxel was the first member of a novel class of cytotoxics, the
taxanes, that stabilise microtubules, causing cell cycle arrest and
apoptosis (Rowinsky et al, 1993). The approved taxanes, paclitaxel
and docetaxel, have a broad spectrum of antitumour activity both
as single agents and in combination, and are widely used for
cancer treatment (Choy, 2001). The clinical use of these agents,
however, is limited by drug resistance and toxicities which include
myelosuppression and peripheral neuropathy (Rowinsky et al,
1993). Therefore paclitaxel derivates have been synthesised, with
the goal of achieving a broader spectrum of antitumour activity
and a more favourable toxicity profile (Rose et al, 2001).
BMS-188797 is a novel, second-generation taxane which
possesses a single structural modification from paclitaxel at the
C-4 position to form the 4-desacetyl-4-methyl carbonate derivate
of paclitaxel. BMS-188797, like paclitaxel, causes G2/M cell cycle
arrest and exhibits potent antiproliferative activity against human
tumour cell lines highly resistant to paclitaxel, either from
overexpression of P-glycoprotein or because of specific mutations
in beta-tubulin. This could be confirmed by the potent in vivo
activity reported for BMS-188797 in paclitaxel-resistant tumour
models in mice (Rose et al, 2001). A phase I study of BMS-188797
(1-h infusion given every 3 weeks) showed a maximum tolerated
dose (MTD) of 175mgm
 2 (Sullivan et al, 2000).
Paclitaxel has been successfully combined with many clinically
noncross-resistant agents, including the platinums, the latter
especially in ovarian cancer (Neijt et al, 2000; Piccart et al, 2000;
du Bois et al, 2003), breast cancer (Rosati et al, 2000), and non-
small-cell lung cancer (NSCLC) (Smit et al, 2003). Consequently,
the combination of platinum and BMS-188797 was evaluated. The
first phase I combination study reported an MTD of 125mgm
 2
BMS-188797 with carboplatin AUC 5, every 3 weeks (Sullivan et al,
2001). Dose-limiting toxicities (DLT) were febrile neutropenia and
slow recovery from neutropenia. Therefore, further effort was
undertaken to develop a combination utilising the less myelo-
suppressive platinum analogue cisplatin.
Here we report a phase I study evaluating the combination of
escalating doses of BMS-188797 as a 1-h infusion followed by
cisplatin at a standard dose of 75mgm
 2 given every 3 weeks in
patients with advanced solid tumours.
PATIENTS AND METHODS
Eligibility criteria
The following inclusion criteria had to be met: Written informed
consent, histologically/cytologically confirmed malignant tumour
after failure of standard therapy; measurable/nonmeasurable
disease; adequate bone marrow function (absolute neutrophil
count (ANC) X2000ml
–1; platelets X100,000ml
–1), hepatic func-
tion (bilirubinp1.5mgdl
–1; ALT/AST p2.5 ULN) and renal
function (serum creatinine p1.5 ULN); age X18 years; Eastern
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more than two prior chemotherapy regimens for metastatic disease
and/or 42 prior (neo)adjuvant regimens. No taxane or platinum
therapy was permitted within 4 months prior to study entry.
Patients could not have brain metastases, pre-existing ototoxicity,
pre-existing neuropathy of the National Cancer Institute Common
Toxicity Criteria (NCI CTC, Version 2.0) grade X1 or prior severe
hypersensitivity reaction to agents containing polyoxyethylated
castor oil (Cremophor EL).
Study design and methodology
This study was an open-label, single-centre, phase I, dose-
escalation trial with the primary objective to determine the MTD
and DLT and to recommend a future phase II dose. Secondary
objectives were safety, antitumour activity and pharmacokinetics
of the experimental drug. The study was carried out with ethical
committee approval.
Treatment plan
BMS-188797 administered by a 1-h infusion was followed by a 1-h
infusion of cisplatin starting 30min after the end of the BMS-
188797 infusion; both drugs were given on day 1, every 3 weeks.
Six treatment cycles were planned. Treatment had to be
discontinued upon progression or occurance of intolerable
toxicity.
BMS-188797 was supplied in 50-mg vials containing 50%
Cremophor EL and dehydrated ethanol. The drug was diluted
before infusion with 0.9% NaCl or 5% dextrose to a final
concentration of 0.3–1.2mgml
–1 and administered through
polyethylene-lined administration sets. Cisplatin solution was
further diluted in 250ml 0.9% NaCl. Escalating dose levels of 80,
110 and 150mgm
 2 BMS-188797 were administered to three, 12
and one patient, respectively. No intrapatient dose escalation was
allowed for individual patients.
On day 1 of every cycle the antiemetic therapy with 5HT3-
antagonists and antihypersensitivity premedication consisting of
dexamethasone 20mg, diphenhydramine 50mg (or equivalent)
and cimetidine 300mg or ranitidine 50mg was administered
before BMS-188797 administration. Prehydration consisting of
1000–1500ml 0.9% saline administered over 90min was started
at the same time as the initiation of the 1-h BMS-188797 infusion.
At the end of the BMS-188797 infusion, 250ml mannitol were
administered over 30min. After prehydration and mannitol
infusion, the cisplatin infusion was administered over 1h. Upon
completion of the cisplatin infusion, posthydration consisting
of 1500ml 0.9% saline was administered over 3h. Antiemetic
prophylaxis for delayed emesis was given on days 2–5. Haemato-
poetic growth factors were not administered prophylactically.
For retreatment on day 22, patients had to have an ANC
X1500ml
 1 and a platelet count X100,000ml
–1; with all treatment-
related toxicities (except alopecia) recovered to baseline or to CTC
grade p1. If a patient was unable to meet retreatment criteria on
day 22, treatment was delayed for 1 week for up to 3 weeks. Any
delay 421 days resulted in removal from the study.
Dose-limiting toxicities and MTD
Three patients were treated at each dose level (DL) prior to dose
escalation. If one DLT was observed during the first course of
therapy in one of these three patients, then three additional
patients were treated. If no further DLT occurred, the next DL was
opened. If the total number of patients with DLT at any DL was
two or higher, then dose escalation was terminated and additional
patients were enrolled at the next lower DL. The MTD was defined
as the DL at which none of the three or one of six patients
experienced a DLT. Once the MTD had been established, accrual at
the respective DL was expanded to determine its suitability as the
recommended phase II dose.
The DLT was defined as first-course toxicity with ANC
o500ml
 1 for X5 days, or febrile neutropenia (fever 438.51C
and ANC o1000ml
 1), or thrombocytopenia o25,000ml
–1;o r
bleeding requiring platelet transfusion, or any other drug-related
grade X3 toxicity except fatigue/asthenia, transient arthralgia/
myalgia, or grade 3 AST/ALT elevation (resolving to baseline
within 3 weeks). Furthermore, delayed recovery from toxicity
related to treatment with BMS-188797 and cisplatin that delayed
scheduled retreatment for 21 days or longer was regarded as DLT.
Dose modifications
Patients experiencing DLT (excluding grade 3 neuropathy) could
be retreated but with a reduced dose in subsequent courses. No
more than two dose reductions were permitted. No dose re-
escalation was allowed. Toxicities requiring a BMS-188797 dose
reduction by one DL were: ANC o500ml
–1 for X5 days, febrile
neutropenia, platelets o25,000ml
–1, grade X3 thrombocytopenia
with bleeding requiring transfusion, grade X3 diarrhoea, and
grade 2 neuropathy. Toxicities resulting in decreased cisplatin dose
(50mgm
 2) were grade X3 nausea/vomiting (despite medical
intervention) and grade 2 neuropathy. Toxicities resulting in
treatment discontinuation were recurrent grade X3 nausea/
vomiting and grade 2 neuropathy despite dose reduction, grade
X3 neuropathy, inner ear/hearing, toxicity, and elevated creati-
nine.
Toxicity and response evaluation
Toxicity was evaluated according to NCI CTC (Vers. 2.0; revised
April 30, 1999) in all patients receiving study drug. Tumour
measurement was performed in patients with measurable disease
after every other cycle; response was assessed according to World
Health Organization (WHO) criteria
. Ascites or serum tumour
marker elevations were not considered in the assessment of
response status except in case of progressive disease or complete
remission when both had to be normalised. Patients evaluable for
response had to have completed at least two courses of treatment
or have disease progression.
Sample collection and drug analysis
In all, 5ml of blood were collected for pharmacokinectic analysis
using Becton-Dickenson Vacutainers
s that contained K3EDTA as
the anticoagulant. Blood sampling for pharmacokinetics analysis
was performed in all patients during cycle 1. Serial blood samples
were drawn at the following times relative to the start of the 1h
infusion of BMS-188797: predose, 30min, 58min (drawn prior to
the end of the infusion), and 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 24, 48 and
72h. Within 1h of collection, the plasma was separated by
centrifugation at 1000rpm for 15min at 41C. Plasma was stored
at or below 201C until analysis. Plasma samples were analysed
for BMS-188797 concentrations by HPLC. After the addition of
internal standard, BMS-183061, to 1.0ml of plasma, the sample
was loaded onto a CN-U solid-phase extraction column. The
compounds were eluted with 0.1% formic acid in methanol, the
eluate evaporated to dryness, and the residue reconstituted.
Chromatographic separation of the compounds was achieved on
a YMC-ODS-AQ, 4.6 150mm, 3mm column using a mobile phase
containing 30% water in acetonitrile. Detection was by ultraviolet
absorbance at 228nm. The standard curve range was 2–
1000ngml
 1. The coefficient of variation (CV) for the between-
and within-run precision for analytical quality control samples
were no greater than 3.0 and 7.1%, respectively
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Estimates of pharmacokinetic parameters for BMS-188797 were
derived from individual concentration–time data sets by non-
compartmental analyses (Gibaldi and Perrier, 1982). The values of
the maximum plasma concentration (Cmax) were recorded directly
from experimental observations. The area under the plasma
concentration vs. time curve from time zero to the time of the
last measurable concentration T (AUC0-T) was calculated using a
combination of linear and log trapezoidal summations. The first-
order rate constant of decline of BMS-188797 concentrations in the
terminal phase of the plasma concentration–time data set, l, was
estimated by log-linear regression, using no weighting factor, of at
least three data points yielding a minimum mean square error. The
absolute value of l was used to estimate the apparent terminal
elimination half-life, t1/2. The last measurable concentration and
the rate constant, l, were used to extrapolate the AUC0-T to
estimate AUC0-N (the area under the curve from time zero to
infinity). The total body clearance (Cl) was calculated by dividing
the dose by AUC0-N. The volume of distribution at steady state
(VSS) was calculated using standard noncompartmental methods.
RESULTS
Patient characteristics
A total of 16 patients entered the trial and patient characteristics are
summarised in Table 1. Median age was 61 years (range, 43–69),
and all but one patient had a good performance status (ECOG 0-1).
Patients had a variety of diagnoses, with ovarian neoplasm being
the most frequent (six of 16 patients), four patients had NSCLC,
two patients suffered from cancer of unknown primary (CUP), and
one patient each had ovarian sarcoma, cervical cancer, urachus
carcinoma and breast cancer. All patients with ovarian cancer had
been treated previously with chemotherapy, with one patient
having received carboplatin/cyclophosphamide and five patients
being treated with carboplatin/paclitaxel. Of these five patients, one
had received further topotecan and carboplatin/epirubicin therapy
and one had received second-line treosulfan. Prior irradiation had
been administered to three patients with breast, cervical and lung
cancer. Prior tamoxifen had been given to two patients, one with
breast cancer after irradiation and one with ovarian cancer after
having received three prior chemotherapy regimens. Seven patients
with lung cancer (three), CUP (two), urachus carcinoma and
ovarian sarcoma had not received any prior therapy at study entry.
Dose escalation
Dose escalation for BMS-188797 started at DLDL 1 80mgm
 2,
which, at the time of study commencement, was shown to be safe
and active from previous phase I trials. Cisplatin was administered
at a fixed standard dose of 75mgm
 2. At the 80-mgm
 2 DL, three
patients received 19 courses. A total of 12 patients received 48
cycles at DL 2 (110mgm
 2 BMS-188797) and one patient received
two cycles at DL 3 (150mgm
 2 BMS-188797).
Dose-limiting toxicities and MTD
None of the three patients treated at DL 1 (80mgm
 2 BMS-
188797) experienced a DLT. Consequently, the dose of BMS-
188797 was escalated to 110mgm
 2. The second patient entered in
this cohort experienced grade 3 diarrhoea and nausea. She received
i.v. fluids, loperamide, dexamethson and metoclopramide and
recovered within 4 days. According to protocol, a total of six
patients had to be accrued at the same DL. None of the additional
patients experienced a DLT, so the study could proceed to
150mgm
 2. The first patient entered in this cohort experienced a
very severe episode of febrile neutropenia with e.coli-sepsis (SIRS
criteria) and near fatal colitis, requiring i.v. treatment with fresh
frozen plasma, ATIII, i.v. antibiotics and parenteral nutrition
during the second course. Although according to the protocol
DLTs were predefined toxicities occurring during course 1 only, it
was decided to consider this toxicity a DLT due to its severity.
Considering this nearly fatal adverse event combined with the
ongoing observation that at the 110mgm
 2 DL, neutropenia was
already increasing in severity over subsequent courses, we decided
to prematurely close the 150mgm
 2 DL and stop further dose
escalation of BMS-188797. Therefore 110mgm
 2 was considered
the MTD of BMS-188797 in combination with cisplatin
(75mgm
 2). According to protocol, six additional patients were
enrolled at the expanded 110mgm
 2 DL. Since no further DLTs
occurred, 110mgm
 2 BMS-188797 in combination with cisplatin
(75mgm
 2), given as a 1-h infusion every 3 weeks was defined as
the recommended dose for future phase II trials. Data on DLTs and
MTD are summarised in Table 2.
Table 1 Patient characteristics
Number of patients (%) (n¼16)
Age (years) – median (range) 61 (43–69)
Performance status
0 11 (69)
1 4 (25)
2 1 (6 [TSK1])
Sex
Male 5 (31)
Female 11 (69)
Prior therapy
Radiotherapy 3 (19)
Chemotherapy only 6 (38)
No prior therapy 7 (44)
Tumour type
Ovarian carcinoma 6
Ovarian sarcoma 1
Non-small-cell lung cancer 4
Cancer of unknown primary 2
Carcinoma of the cervix 1
Urachus carcinoma 1
Breast cancer 1
Table 2 Dose-limiting toxicities (DLTs) and maximum tolerated dose
Dose
level BMS-188797 Cisplatin
No. of patients
enrolled
No. of cycles
administered DLT observed in n patients MTD
DL 1 80mgm
 2 75mgm
 2 31 9 — —
DL 2 110mgm
 2 75mgm
 2 12 48 Diarrhoea G3 (1 patient) MTD
DL 3 150mgm
 2 75mgm
 2 1 2 Neutropenia G4, febrile neutropenia,
sepsis, colitis G3 (one patient
a)
—
aToxicity was observed in second treatment cycle, but was considered DLT due to its life-threatening nature. MTD-level printed in bold.
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Grade 3/4 haematologic toxicities were observed with leukocyto-
penia and neutropenia at every DL investigated. The median time
to the neutrophil nadir was 12, 14 and 8 days in DL 1, DL 2 and DL
3, respectively. The median duration of neutropenia was 4, 8 and 4
days at the respective DLs. Grade 4 neutropenia was observed in
four out of 12 patients at the 110mgm
 2 dose level. Out of these
four patients, two experienced grade 4 neutropenia for more than 5
days, which would have been defined as DLT if occurring during
the first treatment cycle. As described above, this observation of
prolonged neutropenia, increasing in severity at DL 2, confirmed
our decision to terminate further dose escalation and expand
accrual to the 110mgm
 2 DL for further phase II recommenda-
tion. Grade 4 neutropenia and febrile neutropenia resulting in
sepsis was observed in the first patient entering DL 3
(150mgm
 2). The same patient experienced the only observed
episode of grade 3 thrombocytopenia. No further grade 3/4
thrombocytopenia or anaemia was observed at any DL.
In this study, one grade 4 nonhaematologic toxicity, peritonitis
without neutropenia, was observed. This toxicity, however, was
not considered study drug related, but related to the underlying
disease. No other grade 4 nonhaematologic toxicities occurred.
Grade 3 nonhaematologic toxicities were observed in only one
cycle per patient as follows: At the 80mgm
 2 DL, one patient, who
had previously been treated with carboplatin and paclitaxel
showed auditory/hearing toxicity. At the 110mgm
 2 DL grade 3
diarrhoea, nausea, infection without neutropenia, and fever
occurred in one of 12 patients. Together with the haematologic
toxicity observed at this DL, this DLT of grade 3 diarrhoea and
nausea confirmed the designation of 110mgm
 2 as the MTD.
Grade 3 sensory and motor neuropathy was observed in two
patients at the 110mgm
 2 DL only. Neither patients had received
prior taxane-containing chemotherapy and both experienced
neuropathy in the last treatment cycle. One patient had sensory
and motor neuropathy during cycle 4. Treatment was discontinued
in this patient after cycle 4 due to disease progression. The second
patient developed sensory neuropathy at cycle 6, just before
treatment completion and after achieving a complete remission.
Neuropathy was still present in this patient 4 months after the last
dose of study drug. Toxicity experienced by the only patient
entering the 150mgm
 2 DL is described above.
All patients but one experienced alopecia with the earliest onset
at cycle 1 and the latest at cycle 6. Prophylactic premedication with
steroids and H1/H2-antagonists was administered to all patients.
Mild hypersensitivity reactions, grade 2 rash and dyspnea, were
observed in only one patient in two subsequent cycles at the 110-
mgm
 2 DL, leading to temporary treatment interruption (for 24
and 1h, respectively). Four additional courses were given without
any further hypersensitivity reaction observed, but these courses
were administered at a reduced dose of BMS-188797 (80mgm
 2)
due to grade 4 neutropenia.
Dose delay and treatment duration
In this trial only two cycles had to be delayed, one for logistical
reasons and one due to urinary infection One patient experienced
a mild hypersensitivity reaction during the second and third cycle,
so treatment was interrupted temporarily for 24 and 1h,
respectively, and then resumed. Dose reduction of BMS-188797
was necessary in two patients at DL 2 (110mgm
 2). One patient
experienced DLT (grade 3 nausea and diarrhoea) and one patient
had grade 4 neutropenia lasting 7 days. Since no re-escalation was
foreseen, seven out of 69 courses were given at reduced doses of
BMS-188797. Cisplatin was administered at the full dose
(75mgm
 2) at every DL to all patients. A median of five cycles
were administered per patient (range, 1–6) and treatment was
completed as planned in seven patients. Treatment was discon-
tinued because of disease progression in six patients, and two
patients died within 30 days of their last therapy due to disease
progression.
Two patients discontinued treatment due to adverse side effects
(one patient had grade 3 hearing loss and the other had grade 3
nausea, grade 2 vomiting, and fatigue).
Antitumor activity
At DL 1, three patients with ovarian cancer, NSCLC, and CUP
achieved stable disease as their best response. At DL 2 (BMS-
188797 110mgm
 2) three complete remissions were observed in
patients with ovarian (two patients) and cervical cancer (one). One
partial response was observed in another patient with ovarian
cancer. Stable disease was observed in two patients with urachus
carcinoma and NSCLC. Four patients with lung cancer (two
patients), ovarian sarcoma, and CUP had progressive disease. At
DL 3 (BMS-188797 150mgm
 2) the only patient treated who was
suffering from CUP had disease progression.
Pharmacokinetic analyses
Evaluable plasma concentration–time profiles were obtained from
all 16 patients during the first cycle of treatment. Plasma
concentrations were quantifiable in all patients through 72h.
Mean plasma concentration–time profiles of BMS-188797 are
shown in Figure 1 and mean BMS-188797 pharmacokinetic
parameters are listed in Table 3. The pharmacokinetics of BMS-
188797 appeared independent of dose through the 110mgm
 2 DL,
but not through the 150mgm
 2 DL. The mean7s.d. values for
clearance, volume of distribution at steady state and terminal
half-life of the three dose groups during cycle 1 were
317760mlmin
 1m
 2, 258796lm
 2 and 30.877.7h, respec-
tively. At the recommended phase II dose of 110mgm
 2,
interpatient variability in the principal pharmacokinetic para-
meters was moderate, with coefficients of variation percentages of
19, 35 and 24 for CL, VSS and t1/2, respectively. At the 110mgm
 2
DL, there was a 1.8-fold range of AUC0-N values. The relationship
of individual values of Cmax and AUC0-N to dose are plotted in
Figure 2. There was overlap in Cmax and AUC0-N values among the
80 and 110mgm
 2 doses.
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Figure 1 Mean BMS-188797 concentration–time profiles after admin-
istration of BMS-188797 80mgm
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 2, &; 150mgm
 2, n;
in combination with 75mgm
 2 of cisplatin. Error bars indicate s.d.
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Taxanes show a broad spectrum of antitumour activity and are
active both as single agents or in combination with other
noncross-resistant agents, including the platinums (Choy, 2001).
Despite the progress that had been made using taxanes in ovarian
(Neijt et al, 2000; Piccart et al, 2000; du Bois et al, 2003), breast
(Rosati et al, 2000) and lung cancer (Smit et al, 2003), the majority
of patients developed secondary drug resistance and, eventually,
disease progression. Hence the taxane derivatives BMS-188797 and
BMS-184476 were developed, with the aim of reducing toxicity and
a broader spectrum of antitumour activity (Rose et al, 2001). Phase
I single-agent studies have investigated BMS-188797 administered
in 3-weekly (Sullivan et al, 2000) and weekly treatment intervals
(Goldstein et al, 2001; Advani et al, 2003). The final report by
Advani et al (2003) suggested an MTD of BMS-188797 of
50mgm
 2 for weekly administration. For the 3-weekly treatment
schedule, an MTD of 175mgm
 2 was determined (Sullivan et al,
2000). At the start of this phase I combination study of BMS-
188797 and cisplatin, the phase I single-agent trial investigating 3-
weekly treatment intervals was still actively recruiting patients at
the 175mgm
 2 DL, and the interim analysis suggested that BMS-
188797 80–100mgm
 2 would be safe for subsequent combination
studies.
Since the combination of taxanes and platinum compounds have
shown a broad spectrum of antitumour activity, phase I studies
investigating weekly and 3-weekly treatment intervals of BMS-
188797 in combination with carboplatin administered every 3
weeks were initiated. Preliminary data of weekly BMS-188797
administration with carboplatin reported DL, prolonged grade 4
neutropenia and delayed haematological recovery at DLs AUC
6/33mgm
 2 and AUC 5/43mgm
 2 (Advani et al, 2002). The phase
I study investigating the 3-weekly administration of both drugs
reported febrile neutropenia and slow recovery from neutropenia
to be DL. The MTD was carboplatin AUC 5/BMS-188797
125mgm
 2 (Sullivan et al, 2001). In summary, all BMS-188797
phase I studies reported so far have shown neutropenia to be the
main DLT. Therefore, this phase I study was undertaken to
investigate the combination of BMS-188797 with the potentially
less myelosuppressive platinum analogue cisplatin. However, the
study failed to show that the combination of standard-dose
cisplatin (75mgm
 2) with BMS-188797 was less myelosuppressive.
Dose-limiting toxicities were observed from DL 2 on (BMS-188797
110mgm
 2), and further dose escalation could not be achieved. Of
the 12 patients treated at the MTD level of BMS-188797
110mgm
 2, two needed dose reduction for grade 3 diarrheoa/
nausea and for long-lasting neutropenia, respectively, and treat-
ment cycles had to be delayed in one additional patient for urinary
tract infection. At this DL, another three patients experienced
prolonged and increasingly severe neutropenia over the course of
treatment. It was therefore unlikely that further dose escalation to
the 150mgm
2 DL could be safely accomplished and our earlier
decision to prematurely close the 150-mgm
 2 DL was confirmed.
Thus, the MTD was determined to be BMS-188797 110mgm
 2 in
combination with cisplatin 75mgm
 2, given every 3 weeks. This
dose was slightly lower than the 125-mgm
 2 dose of BMS-188797
achieved in combination with carboplatin AUC 5 in the study
reported by Sullivan et al (2001). Similarly, a better safety profile
has also been demonstrated for carboplatin/paclitaxel combina-
tions in patients with ovarian cancer when compared to cisplatin/
paclitaxel (du Bois et al, 2003). The observed toxicity profile of
cisplatin/BMS-188797 was rather similar to cisplatin/paclitaxel and
the phase I trial presented here could not show an improved safety
profile. This comparison, however, can only be performed on a
qualitative basis, considering the early phase of clinical develop-
ment and the limited number of patients treated with BMS-188797/
Table 3 Pharmacokinetic parameters of BMS-188797 in patients
Dose group (mgm 2) No. of patients Cmax (ngml 1) AUC0-N (hngml 1) Cl (mlmin 1m 2) t1/2 (h) VSS (lm 2)
80 3 26507690
(1925, 3300)
40017184
(3856, 4208)
333714
(317, 344)
31.0711.7
(18.1, 40.8)
3317135
(214, 478)
110 12 33717591
(2462, 4162)
586871055
(4195, 7665)
322760
(234, 437)
30.677.5
(14.4, 42.2)
244786
(115, 395)
150 1 5773
NA
12155
NA
206
NA
31.4
NA
209
NA
NA¼not applicable. Data are means7s.d. with ranges in parentheses.
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Figure 2 Individual BMS-188797 Cmax and AUC values, J; fit of the
data derived from linear least squares regression, - - -.
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scisplatin. However, activity was observed at the MTD of BMS-
188797/cisplatin in several tumours, which needs further evalua-
tion. Although no conclusions can be drawn from this small
sample size, larger phase II studies could be planned to gain
further evidence of activity and to support the decision to compare
this new taxane analogue plus a platinum compound to paclitaxel
plus a platinum drug.
The overall pharmacokinetics of BMS-188797 combined with
cisplatin in this study were similar to those of BMS-188797 as a
single agent and were characterised by a large volume of
distribution and a long apparent terminal elimination half-life
(Advani et al, 2003). However, the mean exposure in patients was
lower in this study than in the single-agent studies or in a study of
BMS-188797 in combination with carboplatin (Advani et al, 2003).
Cisplatin would not be expected to increase the clearance of BMS-
188797. However, one of the limitations of this study was that we
did not look for interactions between both compounds and did
not measure platinum pharmakokinetics. The pharmacokinetics of
BMS-188797 in combination with cisplatin in this study appeared
linear through a DL of 110mgm
 2. Firm conclusion for higher
doses coud not be drawn due to the fact that only one patient
was treated with 150mgm
 2. The clearance in this patient
was approximately one-third lower than that in patients at 80
or 110mgm
 2 which might have attributed to the serious course
of toxicity.
Another candidate for further trials might be the second novel
paclitaxel derivative, BMS-184476, a 7-methylthiomethyl ether of
paclitaxel, which was also investigated in single-agent phase I trials
(Plummer et al, 2002) and in combination with cisplatin (Sun et al,
2003) and carboplatin (Bilenker et al, 2004). Similar to our results,
neutropenia and diarrhoea were the DLTs for BMS-184476 in
combination with cisplatin; other toxicities were comparable with
paclitaxel/cisplatin. The occurrence of diarrhoea, which was noted
also in the single-agent trials with BMS-184476 and BMS-188797, is
unusual for paclitaxel treatment and might confirm the in vitro
findings suggesting that the paclitaxel analogues have the ability to
circumvent the P-glycoprotein pump, which is highly expressed
in the colon mucosa (Thiebaut et al, 1987). It may be of interest to
test these agents in tumours in which resistance is specifically
associated with the multidrug-resistance phenotype.
In conclusion, our phase I trial showed that 3-weekly adminis-
tration of BMS-188797 110mgm
 2 in combination with cisplatin
75mgm
 2 is active and safe and is recommended for further phase
II trials. These initial findings warrant more extensive investigation
into the activity of BMS-188797/cisplatin, particularly in patients
with platinum-sensitive tumours not responding to paclitaxel.
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